Skip to content
biosimilar development

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The Biosimilars Market Report Is Available Now!
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

Recent Posts

  • Delving into Misleading or Disparaging Information on Biosimilars July 29, 2020
  • Interchangeability, Switching, and What Happens Next July 24, 2020
  • Adalimumab Biosimilar Approval for Mylan and Fujifilm Kyowa Kirin July 10, 2020
  • Biosimilars and Shared-Savings Programs July 9, 2020
  • Bevacizumab Biosimilar Launch and Development Still a Risky Proposition July 8, 2020
  • Biosimilar Etanercept: Amgen’s Victory in Federal Appeals Court Further Delays Launch July 2, 2020
  • COVID-19 Pandemic Is not Necessarily an Opportunity for Biosimilars June 17, 2020
  • Amgen Settles With Alexion on Soliris Biosimilar, Dropping Litigation and Getting a Release Date June 16, 2020
  • New Entrant into Insulin Market Wants to File as Biosimilar in 2022 June 15, 2020
  • Mylan/Biocon’s Insulin Drug Saga Ends With an Approval June 12, 2020

Recent Comments

Federal Appeals Cour… on An Interesting Comparison: The…
Federal Appeals Cour… on An Interesting Comparison: The…
Prof. Dr. Arnold G.… on Biosimilar Switching: The Evid…
STEVEN J. MILLER on Prescription Abandonment and t…
Nesta on Bevacizumab ASP Pricing now Dr…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • Biosimilar Approval Status
  • Interchangeability, Switching, and What Happens Next
  • An Interesting Comparison: The Latest Data on US and EU Biosimilar Uptake
  • Bevacizumab ASP Pricing now Dropping With Biosimilar Entries
  • Nyvepria
  • What Is the Biosimilar Pegfilgrastim Market Opportunity?
  • Apotex/Apobiologix: Success in Canada, but Are They Shelving Biosimilars in the US?
  • The Evolution of the Biosimilars Market
  • New Entrant into Insulin Market Wants to File as Biosimilar in 2022
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2015-2020 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.